Correlation of serum PTTG1 expression level with clinicopathological features and prognosis in patients with laryngeal cancer
-
摘要: 目的 探讨喉癌患者血清垂体肿瘤转化基因(PTTG1)表达水平与临床病理特征及预后的相关性。方法 采用酶联免疫吸附法检测80例喉癌患者及60例声带息肉患者血清PTTG1的表达水平，分析喉癌患者临床病理特征与血清PTTG1表达水平的关系，Cox回归分析影响喉癌预后的相关因素。结果 血清PTTG1表达水平在喉癌患者明显高于声带息肉患者，差异有统计学意义(P < 0.05)。淋巴结转移、肿瘤TNM分期越高及分化程度越低，患者血清PTTG1表达水平越高(P < 0.05)。预后生存分析中，单因素分析结果显示淋巴结转移、肿瘤TNM分期、分化程度、肿瘤直径及PTTG1表达与喉癌预后有关(P < 0.01)；Cox多因素回归分析结果显示淋巴结转移(HR=2.651，95%CI1.452~4.823，P=0.002)、肿瘤TNM分期高(HR=2.944，95%CI 1.155~6.189，P=0.026)、分化程度低(HR=1.620，95%CI 1.133~2.169，P=0.003)及PTTG1高表达(HR=3.511，95%CI 1.432~7.156，P < 0.001)均是影响喉癌患者预后的危险因素。结论 血清PTTG1的表达水平可能与喉癌患者的临床病理特征及预后密切相关，其高表达可能是喉癌患者预后不良的指标之一。Abstract: Objective To investigate the correlation between the expression level of serum pituitary tumor transforming gene(PTTG1) and clinicopathological characteristics and prognosis in patients with laryngeal cancer.Method Enzyme-linked immunosorbent assay was used to detect the expression of serum PTTG1 in 80 patients with laryngeal cancer and 60 patients with vocal cord polyps. The relationship between the clinicopathological characteristics of patients with laryngeal cancer and the expression of serum PTTG1 was analyzed. Cox regression analysis was used to analyze related factors affecting the prognosis of laryngeal cancer.Result Serum PTTG1 expression level in patients with laryngeal cancer was significantly higher than that in patients with vocal cord polyps, and the difference was statistically significant(P < 0.05). The higher the lymph node metastasis, the higher the tumor TNM stage, and the lower the degree of differentiation, the higher the serum PTTG1 expression level(P < 0.05). In the prognostic survival analysis, univariate analysis showed that lymph node metastasis, tumor TNM stage, degree of differentiation, tumor diameter, and expression of PTTG1 were related to the prognosis of laryngeal cancer(P < 0.01). Cox regression multivariate showed lymph node metastasis(HR=2.651, 95%CI1.452-4.823, P=0.002), high tumor TNM stage(HR=2.944, 95%CI 1.155-6.189, P=0.026), and low differentiation(HR=1.620, 95%CI 1.133-2.169, P=0.003) and high PTTG1 expression(HR=3.511, 95%CI 1.432-7.156, P < 0.001) were risk factors affecting the prognosis of patients with laryngeal cancer.Conclusion The expression level of serum PTTG1 may be closely related to the clinicopathological characteristics and prognosis of patients with laryngeal cancer, and its high expression may be one of the indicators of poor prognosis of patients with laryngeal cancer.
-
-
表 1 喉癌组患者临床病理特征与血清PTTG1表达水平的关系
变量 例数 PTTG1/(pg·mL-1) Z 性别 -0.670 男 66 162.64(136.10，256.68) 女 14 177.69(134.25，247.41) 年龄/岁 -0.154 ≤60 43 159.72(126.28，248.12) >60 37 170.87(130.21，267.43) 淋巴结转移 -3.7641) N+ 46 180.17(154.67，289.38) N0 34 147.29(127.23，242.85) 肿瘤直径/cm -0.711 ≤3 35 163.36(137.28，259.33) >3 45 178.61(130.28，244.67) 肿瘤分期 -2.2381) Ⅰ+Ⅱ 34 162.36(122.61，213.74) Ⅲ+Ⅳ 46 283.53(158.36，290.41) 肿瘤分化程度 -4.2251) 高分化或中分化 38 156.12(124.17，211.81) 低分化 42 227.59(157.73，318.39) 肿瘤部位 -0.528 声门上型或声门型 76 165.37(128.68，237.39) 声门下型 4 172.85(147.31，265.36) 组间比较1)P < 0.05。 
下载: 导出CSV
表 2 喉癌患者预后的单因素分析结果
因素 5年生存率/% 单因素分析 χ2 P 性别 男 69.8 0.694 0.717 女 72.9 年龄/岁 ≤60 71.6 0.511 0.802 >60 68.4 淋巴结转移 N+ 58.3 8.771 0.003 N0 76.7 肿瘤直径/cm ≤3 71.2 7.733 0.005 >3 56.8 肿瘤TNM分期 Ⅰ+Ⅱ 79.5 16.339 < 0.001 Ⅲ+Ⅳ 50.2 肿瘤分化程度 低分化 51.1 10.225 0.001 高或中分化 73.9 肿瘤部位 声门上型 68.4 3.026 0.013 声门型 72.1 声门下型 64.3 PTTG1/(pg·mL-1) >141.3 39.2 29.125 < 0.001 ≤141.3 78.9
下载: 导出CSV
表 3 影响喉癌患者预后的Cox回归分析结果
变量 B Wald χ2 SE HR HR 95%CI P 肿瘤直径 0.612 1.220 0.554 1.026 0.820~5.124 0.519 分化程度 0.415 6.280 0.199 1.620 1.133~2.169 0.003 肿瘤TNM分期 0.568 4.459 0.269 2.944 1.155~6.189 0.026 淋巴结转移 0.894 7.526 0.326 2.651 1.452~4.823 0.002 PTTG1表达水平 0.557 17.540 0.133 3.511 1.432~7.156 < 0.001
下载: 导出CSV
-
[1] Taito M, Taito S, Banno M, et al. Voice rehabilitation for laryngeal cancer after radiotherapy: a systematic review and meta-analysis[J]. Eur Arch Otorhinolaryngol, 2019, 276(6): 1573-1583. doi: 10.1007/s00405-019-05452-2
[2] Porto de Toledo I, Pantoja LLQ, Luchesi KF, et al. Deglutition disorders as a consequence of head and neck cancer therapies: a systematic review and meta-analysis[J]. Support Care Cancer, 2019, 27(10): 3681-3700. doi: 10.1007/s00520-019-04920-z
[3] 张文超, 张强, 岳玖玲, 等. 诱导化疗后进展期声门上喉癌切缘及分子标志物研究[J]. 天津医药, 2019, 47(5): 533-537, 566. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYZ201905021.htm
[4] Che J, Wang Y, Zhang X, et al. Comparative efficacy of six therapies for Hypopharyngeal and laryngeal neoplasms: a network meta-analysis[J]. BMC Cancer, 2019, 19(1): 282. doi: 10.1186/s12885-019-5412-z
[5] Li M, Zhang T, Tan B, et al. Role of postoperative adjuvant radiotherapy for locally advanced laryngeal cancer: a meta-analysis[J]. Acta Otolaryngol, 2019, 139(2): 172-177. doi: 10.1080/00016489.2018.1542159
[6] Gao P, Gong L, Wang X. Induction chemotherapy in patients with resectable laryngeal cancer: A meta-analysis[J]. Mol Clin Oncol, 2018, 9(2): 155-162. doi: 10.3892/mco.2018.1645
[7] Parte S, Virant-Klun I, Patankar M, et al. PTTG1: a Unique Regulator of Stem/Cancer Stem Cells in the Ovary and Ovarian Cancer[J]. Stem Cell Rev Rep, 2019, 15(6): 866-879. doi: 10.1007/s12015-019-09911-5
[8] Guo XC, Li L, Gao ZH, et al. The long non-coding RNA PTTG3P promotes growth and metastasis of cervical cancer through PTTG1[J]. Aging(Albany NY), 2019, 11(5): 1333-1341.
[9] Zhi T, Jiang K, Xu X, et al. ECT2/PSMD14/PTTG1 axis promotes the proliferation of glioma through stabilizing E2F1[J]. Neuro Oncol, 2019, 21(4): 462-473. doi: 10.1093/neuonc/noy207
[10] Huang JL, Cao SW, Ou QS, et al. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma[J]. Mol Cancer, 2018, 17(1): 93. doi: 10.1186/s12943-018-0841-x
[11] Romero Arenas MA, Whitsett TG, Aronova A, et al. Protein Expression of PTTG1 as a Diagnostic Biomarker in Adrenocortical Carcinoma[J]. Ann Surg Oncol, 2018, 25(3): 801-807. doi: 10.1245/s10434-017-6297-1
[12] Khan F, Valliani A, Rehman A, et al. Factors Affecting Functional Outcome after Decompressive Craniectomy Performed for Traumatic Brain Injury: A Retrospective, Cross-sectional Study[J]. Asian J Neurosurg, 2018, 13(3): 730-736. doi: 10.4103/ajns.AJNS_6_18
[13] Fu D, Zhang Y, Cui H. Long noncoding RNA CCAT2 is activated by E2F1 and exerts oncogenic properties by interacting with PTTG1 in pituitary adenomas[J]. Am J Cancer Res, 2018, 8(2): 245-255. https://pubmed.ncbi.nlm.nih.gov/29511595/
[14] Xu X, Cao L, Zhang Y, et al. Network analysis of DEGs and verification experiments reveal the notable roles of PTTG1 and MMP9 in lung cancer[J]. Oncol Lett, 2018, 15(1): 257-263. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768071/
[15] Romero Arenas MA, Whitsett TG, Aronova A, et al. Protein Expression of PTTG1 as a Diagnostic Biomarker in Adrenocortical Carcinoma[J]. Ann Surg Oncol, 2018, 25(3): 801-807. doi: 10.1245/s10434-017-6297-1
[16] Wang F, Xuan X, Li S, et al. PTTG1 cooperated with GLI1 leads to epithelial-mesenchymal transition in esophageal squamous cell cancer[J]. Oncotarget, 2017, 8(54): 92388-92400. doi: 10.18632/oncotarget.21343
-